Form 4 for DNA Ginkgo Bioworks Holdings, Inc.
Accepted 2022-11-10 00:00:00 ET · period of report 2022-09-30 · accession 0000899243-22-035555 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-10 | 2022-09-30 | DNA | Kewalramani Reshma | Dir | M - OptEx | — | +9,818 | 80.7K | +14% | — |
| D | 2022-11-10 | 2022-09-30 | DNA | Kewalramani Reshma | Dir | M - OptEx | $0.00 | -9,818 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-09-30 | M | A | 9,818 | — | 80,739 | D | — | — | (F1) Represents the conversion of restricted stock units ("RSUs") into Class A common stock. |
| 2 | Derivative | Restricted Stock Units | 2022-09-30 | M | D | 9,818 | $0.00 | 0 | D | — · — to — | 9,818 Class A Common Stock | (F2) Each RSU represents a contingent right to receive one share of Class A common stock. (F3) In accordance with an agreement between the Reporting Person and the issuer to delay vesting of the RSUs, the RSUs vested on September 30, 2022. |